Using Machine Learning Algorithms to Predict Immunotherapy Response in Patients with Advanced Melanoma
暂无分享,去创建一个
D. Rimm | N. Coudray | A. Tsirigos | Douglas B. Johnson | I. Osman | A. Pavlick | G. Jour | L. Wheless | J. Weber | J. Zhong | P. Johannet | Douglas Donnelly | Irineu Illa-Bochaca | Yuhe Xia | J. Patrinely | Sofia Nomikou | D. Donnelly
[1] N. Razavian,et al. Predicting endometrial cancer subtypes and molecular features from histopathology images using multi-resolution deep learning models , 2020, bioRxiv.
[2] A. Regev,et al. Integrative molecular and clinical modeling of clinical outcomes to PD1 blockade in patients with metastatic melanoma , 2019, Nature Medicine.
[3] D. Rimm,et al. An open source automated tumor infiltrating lymphocyte algorithm for prognosis in melanoma , 2019, Nature Communications.
[4] Jing Wang,et al. Deep Learning Based on Standard H&E Images of Primary Melanoma Tumors Identifies Patients at Risk for Visceral Recurrence and Death , 2019, Clinical Cancer Research.
[5] Yan Jing,et al. Artificial intelligence in dermatology: past, present, and future , 2019, Chinese medical journal.
[6] J. Larkin,et al. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. , 2019, The Lancet. Oncology.
[7] Thomas J. Fuchs,et al. Clinical-grade computational pathology using weakly supervised deep learning on whole slide images , 2019, Nature Medicine.
[8] Nathalie Harder,et al. Automatic discovery of image-based signatures for ipilimumab response prediction in malignant melanoma , 2019, Scientific Reports.
[9] N. Razavian,et al. A Deep Learning Approach for Rapid Mutational Screening in Melanoma , 2019, bioRxiv.
[10] C. Brennan,et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.
[11] D. Schadendorf,et al. Nivolumab plus ipilimumab or nivolumab alone versus ipilimumab alone in advanced melanoma (CheckMate 067): 4-year outcomes of a multicentre, randomised, phase 3 trial. , 2018, The Lancet. Oncology.
[12] S. Adams,et al. Predictive Biomarkers for Checkpoint Immunotherapy: Current Status and Challenges for Clinical Application , 2018, Cancer Immunology Research.
[13] N. Razavian,et al. Classification and mutation prediction from non–small cell lung cancer histopathology images using deep learning , 2018, Nature Medicine.
[14] G. Freeman,et al. Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response , 2018, Nature Medicine.
[15] H. Haenssle,et al. Man against machine: diagnostic performance of a deep learning convolutional neural network for dermoscopic melanoma recognition in comparison to 58 dermatologists , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.
[16] Eytan Ruppin,et al. Robust prediction of response to immune checkpoint blockade therapy in metastatic melanoma , 2018, Nature Medicine.
[17] Wei Zhang,et al. Exosomal PD-L1 Contributes to Immunosuppression and is Associated with anti-PD-1 Response , 2018, Nature.
[18] T. Kirchhoff,et al. Primary Melanoma Histologic Subtype: Impact on Survival and Response to Therapy , 2018, Journal of the National Cancer Institute.
[19] D. Milne,et al. Clinical and palliative care outcomes for patients of poor performance status treated with antiprogrammed death‐1 monoclonal antibodies for advanced melanoma , 2017, Asia-Pacific journal of clinical oncology.
[20] V. de Giorgi,et al. Clinicopathological predictors of recurrence in nodular and superficial spreading cutaneous melanoma: a multivariate analysis of 214 cases , 2017, Journal of Translational Medicine.
[21] David M. Woods,et al. Predictors of responses to immune checkpoint blockade in advanced melanoma , 2017, Nature Communications.
[22] J. Malvehy,et al. Prognostic role of the histological subtype of melanoma on the hands and feet in Caucasians , 2017, Melanoma research.
[23] E. Hsueh,et al. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response , 2017, Biomarker Research.
[24] S. Elledge,et al. Tumor aneuploidy correlates with markers of immune evasion and with reduced response to immunotherapy , 2017, Science.
[25] Nassir Navab,et al. Structure-Preserving Color Normalization and Sparse Stain Separation for Histological Images , 2016, IEEE Transactions on Medical Imaging.
[26] J. Soria,et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. , 2016, European journal of cancer.
[27] Bolei Zhou,et al. Learning Deep Features for Discriminative Localization , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).
[28] Sergey Ioffe,et al. Rethinking the Inception Architecture for Computer Vision , 2015, 2016 IEEE Conference on Computer Vision and Pattern Recognition (CVPR).
[29] J. Larkin,et al. Prognostic score for patients with advanced melanoma treated with ipilimumab. , 2015, European journal of cancer.
[30] A. Wilm,et al. LoFreq: a sequence-quality aware, ultra-sensitive variant caller for uncovering cell-population heterogeneity from high-throughput sequencing datasets , 2012, Nucleic acids research.
[31] D. Schadendorf,et al. Improved survival with ipilimumab in patients with metastatic melanoma. , 2010, The New England journal of medicine.
[32] for the Statistics Subcommittee of the NCI—EORTC Worki Diagnostics. REporting recommendations for tumor MARKer prognostic studies (REMARK) , 2005, Nature Clinical Practice Oncology.
[33] Erik Reinhard,et al. Color Transfer between Images , 2001, IEEE Computer Graphics and Applications.